Please use this identifier to cite or link to this item:
Title: Screening, production, and characterization of biologically active secondary metabolite(s) from marine Streptomyces sp. PA9 for antimicrobial, antioxidant, and mosquito larvicidal activity
Authors: Sivarajan, A.
Shanmugasundaram, T.
Sangeetha, M.
Radhakrishnan, M.
Balagurunathan, R.
Keywords: Actinobacteria;Clinical pathogens;Culex quinquefasciatus;FTIR;HPLC;GC–MS
Issue Date: Aug-2019
Publisher: NISCAIR-CSIR, India
Abstract: Bioprospecting of actinobacteria from understudied ecosystems is a promising source for extracting novel bioactive metabolites. A study was undertaken to characterize and analyze the bio-efficacy of actinobacterial extract for antimicrobial, larvicidal, and antioxidant activities. Seven morphologically different actinobacterial cultures isolated from mangrove rhizosphere sediment near Parangipettai, South India, were tested for antimicrobial activity. Bioactive metabolites from one potential strain PA9 were produced by submerged fermentation. The selected Streptomyces sp. PA9 was subjected to the production of crude extract for antimicrobial, larvicidal, and antioxidant activity. The actinobacterial compound was characterized by Fourier transform infrared spectroscopy (FTIR), high-performance liquid chromatography (HPLC), and gas chromatography–mass spectrometry (GC–MS). The PA9 actinobacterial crude extract showed best antimicrobial activity against clinical bacteria, Salmonella typhi (21.6 ± 0.88 mm) and fungi, Candida albicans (26.6 ± 0.88 mm). The PA9 extract showed significant larvicidal activity against Culex quinquefasciatus with LC50=173.21 µg/ml and r2=0.841. The PA9 extract also exhibited antioxidant activity from DPPH (72%) and nitric oxide free radicals (85%). The characterization of the PA9 extract by FTIR analysis showed the presence of possible functional groups. Active compounds were isolated by HPLC and GC–MS with major and minor peaks observed on the basis of retention time. The bio-efficacy of PA9 has warranted further studies to develop a baseline for the drug development.
Page(s): 1319-1326
ISSN: 0975-1033 (Online); 0379-5136 (Print)
Appears in Collections:IJMS Vol.48(08) [August 2019]

Files in This Item:
File Description SizeFormat 
IJMS 48(8) 1319-1326.pdf254.35 kBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.